Evaluation of an ELISA to detect rabies antibodies in orally vaccinated foxes and raccoon dogs sampled in the field

Wasniewski, Marine; Guiot, Anne-Laure; Schereffer, J.L.; Tribout, L.; Mähar, K.; Cliquet, Florence

doi:10.1016/j.jviromet.2012.11.022

Cited by 54 publications

(51 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our study we were required to use a very high vaccine dose (10 8.0 FFU/mL) to increase the likelihood to observe any differences in vaccine uptake in MALT of the oral cavity of the various species at all. This could be the reason why all animals regardless of species exhibited RABV specific antibodies by day 10 pi (Table 3) as measured by the standard RFFIT 53 and the more sensitive ELISA 53,54 , irrespective of the identification of infected cells in the t. palatina. Therefore, other tissues in the oropharyngeal cavity must have been involved in virus uptake and subsequent interaction with the immune system.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Responsiveness of various reservoir species to oral rabies vaccination correlates with differences in vaccine uptake of mucosa associated lymphoid tissues

Kamp

Freuling

Vos³

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Oral rabies vaccination (ORV) is highly effective in foxes and raccoon dogs, whereas for unknown reasons the efficacy of ORV in other reservoir species is less pronounced. To investigate possible variations in species-specific cell tropism and local replication of vaccine virus, different reservoir species including foxes, raccoon dogs, raccoons, mongooses, dogs and skunks were orally immunised with a highly attenuated, high-titred GFP-expressing rabies virus (RABV). Immunofluorescence and RT-qPCR screenings revealed clear differences among species suggesting host specific limitations to ORV. While for responsive species the palatine tonsils (tonsilla palatina) were identified as a main site of virus replication, less virus dissemination was observed in the tonsils of rather refractory species. While our comparison of vaccine virus tropism emphasizes the important role that the tonsilla palatina plays in eliciting an immune response to ORV, our data also indicate that other lymphoid tissues may have a more important role than originally anticipated. Overall, these data support a model in which the susceptibility to oral live RABV vaccine infection of lymphatic tissue is a major determinant in vaccination efficacy. The present results may help to direct future research for improving vaccine uptake and efficacy of oral rabies vaccines under field conditions.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Binding antibodies were detected by rabies virus specific inhibition ELISA according to manufacturer specifications (BioPro Rabies ELISA Ab kit, O.K. Servis BioPro, Prague, Czech Republic) 54 .…”

Section: Diagnostic Assaysmentioning

confidence: 99%

Responsiveness of various reservoir species to oral rabies vaccination correlates with differences in vaccine uptake of mucosa associated lymphoid tissues

Kamp

Freuling

Vos³

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…None of the animals of group 4, which were mock immunized, demonstrated immune responses against the RABV G or MERS-COV S protein, confirming the specificity of the ELISAs. Whereas RABV G-specific ELISA titers are known to predict protection against RABV challenge (47)(48)(49), the protective abilities of the MERS-CoV S-directed antibodies are unknown. We therefore performed VNA assays against MERS-CoV using sera collected on day 35 postimmunization from mice of all four groups (Fig.…”

Section: Construction Of An Attenuated Rabv Expressing the Mers-cov Smentioning

confidence: 99%

One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus

Wirblich

Coleman

Kurup

et al. 2017

J Virol

View full text Add to dashboard Cite

Middle East respiratory syndrome coronavirus (MERS-CoV) emerged in 2012 and is a highly pathogenic respiratory virus. There are no treatment options against MERS-CoV for humans or animals, and there are no large-scale clinical trials for therapies against MERS-CoV. To address this need, we developed an inactivated rabies virus (RABV) that contains the MERS-CoV spike (S) protein expressed on its surface. Our initial recombinant vaccine, BNSP333-S, expresses a full-length wild-type MERS-CoV S protein; however, it showed significantly reduced viral titers compared to those of the parental RABV strain and only low-level incorporation of full-length MERS-CoV S into RABV particles. Therefore, we developed a RABV-MERS vector that contained the MERS-CoV S1 domain of the MERS-CoV S protein fused to the RABV G protein C terminus (BNSP333-S1). BNSP333-S1 grew to titers similar to those of the parental vaccine vector BNSP333, and the RABV G-MERS-CoV S1 fusion protein was efficiently expressed and incorporated into RABV particles. When we vaccinated mice, chemically inactivated BNSP333-S1 induced high-titer neutralizing antibodies. Next, we challenged both vaccinated mice and control mice with MERS-CoV after adenovirus transduction of the human dipeptidyl peptidase 4 (hDPP4) receptor and then analyzed the ability of mice to control MERS-CoV infection. Our results demonstrated that vaccinated mice were fully protected from the MERS-CoV challenge, as indicated by the significantly lower MERS-CoV titers and MERS-CoV and mRNA levels in challenged mice than those in unvaccinated controls. These data establish that an inactivated RABV-MERS S-based vaccine may be effective for use in animals and humans in areas where MERS-CoV is endemic.IMPORTANCE Rabies virus-based vectors have been proven to be efficient dual vaccines against rabies and emergent infectious diseases such as Ebola virus. Here we show that inactivated rabies virus particles containing the MERS-CoV S1 protein induce potent immune responses against MERS-CoV and RABV. This novel vaccine is easy to produce and may be useful to protect target animals, such as camels, as well as humans from deadly MERS-CoV and RABV infections. Our results indicate that this vaccine approach can prevent disease, and the RABV-based vaccine platform may be a valuable tool for timely vaccine development against emerging infectious diseases.

show abstract

“…For the assessment of the actual vaccine-induced immunity the presence of neutralising antibodies in serum is recognised as the most reliable parameter for assessing the efficacy of vaccination because it is closely correlated with protection against rabies infection. Thus, it is considered an efficient and direct estimate of vaccination efficacy in the target population (Wasniewski et al 2013). Traditionally, recommended serological methods include the rapid fluorescent foci inhibition test (RFFIT) (Smith et al 1996) and the fluorescent antibody virus neutralisation test (FAVN) (Cliquet et al 1998).…”

mentioning

confidence: 99%

The field efficiency of oral rabies vaccination in the Lithuanian red fox population from 2006 to 2013

Zienius¹,

Pridotkas²,

Jacevičienė³

et al. 2014

Vet. Med. - Czech

View full text Add to dashboard Cite

ABSTRACT:The objective of the present study was to assess the efficacy of an oral rabies vaccination (ORV) program in the period from 2006 to 2013 based on epidemiological data (Incidence of confirmed rabies in red foxes), biological marker evaluation (presence of tetracycline [TTC] indicating bait uptake), and the assessment of seroconversion (based on ELISA for rabies antibodies) in red foxes in Lithuania. Results were compared between juvenile and adult red foxes, and between the spring (March to May) and autumn (October to December) campaigns. On average, 20 baits/km 2 were distributed over the entire territory of Lithuania. During the entire period

show abstract

Evaluation of an ELISA to detect rabies antibodies in orally vaccinated foxes and raccoon dogs sampled in the field

Cited by 54 publications

References 20 publications

Responsiveness of various reservoir species to oral rabies vaccination correlates with differences in vaccine uptake of mucosa associated lymphoid tissues

Responsiveness of various reservoir species to oral rabies vaccination correlates with differences in vaccine uptake of mucosa associated lymphoid tissues

One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus

The field efficiency of oral rabies vaccination in the Lithuanian red fox population from 2006 to 2013

Contact Info

Product

Resources

About